Dhatchinamoorthy K, Colbert J, Rock K
Front Immunol. 2021; 12:636568.
PMID: 33767702
PMC: 7986854.
DOI: 10.3389/fimmu.2021.636568.
Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F
Cell Mol Immunol. 2021; 18(3):556-565.
PMID: 33473191
PMC: 8027055.
DOI: 10.1038/s41423-021-00634-7.
Goeppert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M
Br J Cancer. 2015; 113(9):1343-9.
PMID: 26461054
PMC: 4815783.
DOI: 10.1038/bjc.2015.337.
Powell A, Horgan P, Edwards J
J Cancer Res Clin Oncol. 2012; 138(5):723-8.
PMID: 22426959
DOI: 10.1007/s00432-012-1192-4.
Schietinger A, Philip M, Liu R, Schreiber K, Schreiber H
J Exp Med. 2010; 207(11):2469-77.
PMID: 20921286
PMC: 2964573.
DOI: 10.1084/jem.20092450.
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.
Poulogiannis G, McIntyre R, Dimitriadi M, Apps J, Wilson C, Ichimura K
Proc Natl Acad Sci U S A. 2010; 107(34):15145-50.
PMID: 20696900
PMC: 2930574.
DOI: 10.1073/pnas.1009941107.
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.
Mendez R, Rodriguez T, Campo A, Monge E, Maleno I, Aptsiauri N
Cancer Immunol Immunother. 2007; 57(5):719-29.
PMID: 17934731
PMC: 11030649.
DOI: 10.1007/s00262-007-0411-3.
Tumor immunoediting and immunosculpting pathways to cancer progression.
Reiman J, Kmieciak M, Manjili M, Knutson K
Semin Cancer Biol. 2007; 17(4):275-87.
PMID: 17662614
PMC: 2742305.
DOI: 10.1016/j.semcancer.2007.06.009.
Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.
Pandha H, Rigg A, John J, Lemoine N
Clin Exp Immunol. 2007; 148(1):127-35.
PMID: 17302733
PMC: 1868855.
DOI: 10.1111/j.1365-2249.2006.03289.x.
High-resolution analysis of HLA class I alterations in colorectal cancer.
Dierssen J, de Miranda N, Mulder A, van Puijenbroek M, Verduyn W, Claas F
BMC Cancer. 2006; 6:233.
PMID: 17014712
PMC: 1599746.
DOI: 10.1186/1471-2407-6-233.
Activation by interferon-gamma of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas.
Donnellan I, Cantrill J, Fraser I, Morris A
Clin Mol Pathol. 1995; 48(1):M40-5.
PMID: 16695974
PMC: 407918.
DOI: 10.1136/mp.48.1.m40.
T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhauser M
Cancer Immunol Immunother. 2005; 54(11):1043-58.
PMID: 15887014
PMC: 11032795.
DOI: 10.1007/s00262-005-0681-6.
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
Diederichsen A, Hjelmborg J, Christensen P, Zeuthen J, Fenger C
Cancer Immunol Immunother. 2003; 52(7):423-8.
PMID: 12695859
PMC: 11032970.
DOI: 10.1007/s00262-003-0388-5.
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem J, Lee P, Kant S, Wieder E, Jiang W, Lu S
J Clin Invest. 2003; 111(5):639-47.
PMID: 12618518
PMC: 151894.
DOI: 10.1172/JCI16398.
The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.
Svane I, Boesen M, ENGEL A
Med Oncol. 2000; 16(4):223-38.
PMID: 10618685
DOI: 10.1007/BF02785868.
Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas.
Jackson P, Green M, Marks C, King R, Hubbard R, Cook M
Gut. 1996; 38(1):85-9.
PMID: 8566865
PMC: 1382984.
DOI: 10.1136/gut.38.1.85.
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
Korkolopoulou P, Kaklamanis L, Pezzella F, Harris A, Gatter K
Br J Cancer. 1996; 73(2):148-53.
PMID: 8546899
PMC: 2074307.
DOI: 10.1038/bjc.1996.28.
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
Seung S, Urban J, Schreiber H
J Exp Med. 1993; 178(3):933-40.
PMID: 8394406
PMC: 2191160.
DOI: 10.1084/jem.178.3.933.
Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.
Vegh Z, Wang P, Vanky F, Hising C, Sjowall K, Larsson B
Cancer Immunol Immunother. 1994; 38(1):71-3.
PMID: 8299122
PMC: 11038081.
DOI: 10.1007/BF01517173.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
Marincola F, Shamamian P, Simonis T, Abati A, Hackett J, ODea T
J Immunother Emphasis Tumor Immunol. 1994; 16(1):13-23.
PMID: 8081556
PMC: 2561308.
DOI: 10.1097/00002371-199407000-00002.